Welcome to our dedicated page for SANUWAVE HEALTH news (Ticker: $SNWV), a resource for investors and traders seeking the latest updates and insights on SANUWAVE HEALTH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SANUWAVE HEALTH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SANUWAVE HEALTH's position in the market.
Rhea-AI Summary
SANUWAVE Health, Inc. announces record-breaking preliminary revenues of $5.7 to $5.9 million for Q1 2024, marking a 51% to 56% increase over Q1 2023. UltraMist revenues surged by over 55%, contributing 95% to total revenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. announces the hiring of Peter Sorensen as CFO, bringing extensive finance, forecasting, and capital markets experience to drive growth in the wound care business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. reports record revenues for Q4 2023 and FY 2023, with significant growth in operating income. The company provides strong revenue growth guidance for Q1 2024 and FY 2024. UltraMIST® systems and consumables drive revenue growth, with a focus on profitable expansion. Adjusted EBITDA shows notable improvement, reflecting operational efficiencies. The company aims for rapid, profitable growth in the upcoming year, expecting substantial revenue increases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. to present Q4 and FY2023 financial results in a live conference call on March 22, 2024. The company, known for its FDA-approved wound care products, invites participants to join the call or access it online. Materials will be available on the company website, with a replay option until April 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. announces stockholders' approval of business combination with SEP Acquisition Corp. at a special meeting. 70.5% of eligible shares voted or abstained, with 99.3% voting 'for' the proposal. CEO Morgan Frank expresses satisfaction with the outcome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. (SNWV) is holding a special meeting of stockholders on February 21, 2024, to vote on the previously announced merger with SEP Acquisition Corp. Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol 'SNWV'. Stockholders of record at the close of business on January 10, 2023, will be entitled to vote at the special meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. (SNWV) announces record preliminary revenues of $6.6 million to $6.8 million for Q4 2023, representing a 20% to 24% increase over Q4 2022. FY 2023 revenue range was $20.0 million to $20.2 million, a 19% to 20% year-over-year increase. UltraMist product line drove Q4 2023 growth, accounting for approximately 95% of total revenues. CEO Morgan Frank expresses optimism for continued success in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.39%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. (SNWV) announces 3rd quarter 2023 results, with a 19% increase in revenue to $5.0 million, driven by UltraMist® systems and consumables. Gross margin at 71%, operating loss down by $2.0 million. Net loss at $23.7 million due to non-cash losses on derivative liabilities. Recent highlights include a merger agreement with Nasdaq-listed company, hiring of industry veteran Andrew Walko, and focus on rapid, profitable growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
-
Rhea-AI Summary
SNWV - SANUWAVE Health, Inc. to Host Live Conference Call to Present Q3 2023 Financial Results. The leading provider of next-generation wound care products will present their Q3 2023 financial results in a live conference call on November 10, 2023, at 8:00AM (ET). Participants can access the call via telephone or an instant Call me™ link. A replay will be available through November 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
News
Rhea-AI Summary
SANUWAVE announces preliminary revenues of $4.7M to $4.9M for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
SANUWAVE HEALTH INC
OTC:SNWV
SNWV Rankings
SNWV Stock Data
22.24M
622.26M
10.73%
10.11%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Eden Prairie
About SNWV
sanuwave, inc. is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. sanuwave's portfolio of products and product candidates activate biologic signaling and angiogenic reponses, including revascularization and microcirculation, helping to restore the body's normal healing processes and regeneration. these devices, based on pulsed acoustic cellular expression (pace™) technology, are being developed and commercialized for use in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions.